LUCD vs. BVS, AXGN, KIDS, NPCE, SMLR, TMCI, CLPT, OM, NNOX, and NYXH
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Bioventus (BVS), AxoGen (AXGN), OrthoPediatrics (KIDS), NeuroPace (NPCE), Semler Scientific (SMLR), Treace Medical Concepts (TMCI), ClearPoint Neuro (CLPT), Outset Medical (OM), Nano-X Imaging (NNOX), and Nyxoah (NYXH). These companies are all part of the "medical equipment" industry.
Lucid Diagnostics vs.
Bioventus (NYSE:BVS) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
Lucid Diagnostics received 12 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 69.35% of users gave Lucid Diagnostics an outperform vote while only 62.00% of users gave Bioventus an outperform vote.
Bioventus currently has a consensus target price of $14.33, suggesting a potential upside of 106.24%. Lucid Diagnostics has a consensus target price of $3.55, suggesting a potential upside of 174.13%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Bioventus.
Bioventus has a net margin of -7.11% compared to Lucid Diagnostics' net margin of -1,069.87%. Bioventus' return on equity of 15.61% beat Lucid Diagnostics' return on equity.
62.9% of Bioventus shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 32.9% of Bioventus shares are owned by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Lucid Diagnostics had 4 more articles in the media than Bioventus. MarketBeat recorded 4 mentions for Lucid Diagnostics and 0 mentions for Bioventus. Lucid Diagnostics' average media sentiment score of 1.14 beat Bioventus' score of 0.00 indicating that Lucid Diagnostics is being referred to more favorably in the news media.
Lucid Diagnostics has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Bioventus has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.
Summary
Lucid Diagnostics beats Bioventus on 13 of the 19 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:LUCD) was last updated on 6/11/2025 by MarketBeat.com Staff
